New Study Fails to Note Rising Risperdal Lawsuit Litigation, Explores Possible Benefits of Use in Children

Published on January 3, 2014 by Laurie Villanueva

Text-Size:A A A+

 

A new study suggests that taking a stimulant medication in combination with an anti-psychotic drug named in Risperdal lawsuit claims may benefit children with ADHD who also have serious behavioral problems, according to a recent HealthDay report.

In an article published January 2nd, findings of the research, which involved the experiences of 168 children, were published in the January issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

The children in the study, who were between the ages of 6 and 12 years old, were diagnosed with ADHD and “had far more significant behavioral issues than the typical child with ADHD alone,” according to one of its authors, who is also a director of clinical trials at Ohio State University’s Nisonger Center. They had displayed past episodes of serious physical aggression in which they either hurt themselves or destroyed property. Individuals who took Risperdal in combination with a stimulant reportedly saw behavioral improvements, according to the study, which also noted the link between the anti-psychotic drug and type-2 diabetes.

Risperdal Gynecomastia Lawsuits Make Waves in Pennsylvania Litigation

Meanwhile, the alleged downsides of Risperdal are making waves in a mounting litigation of claims filed in the U.S. According to court documents, a total of 275 lawsuits, many of which alleging Risperdal gynecomastia complications, are now pending in a consolidated litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas on behalf of individuals who allegedly experienced side effects from the drug. Plaintiffs in these cases similarly allege that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., improperly marketed Risperdal for uses not approved by the U.S. Food and Drug Administration (FDA). The medication was not approved for pediatric uses prior to 2006, for example.

In a recent settlement with the U.S. Department of Justice, the makers of Risperdal paid $2.5 billion in charges related to its marketing of this medication, as well as certain others. Among other things, Johnson & Johnson was accused of promoting the drug for pediatric uses prior to its FDA approval to do so in 2006, as well as to elderly patients with dementia.  It is uncertain whether this may relate to Risperdal gynecomastia claims.

Contact a Lawyer to File a Risperdal Gynecomastia Claim

If you or a loved one experienced Risperdal gynecomastia complications, you may be eligible to file a lawsuit. Call our Firm today to learn more at .